Charles Herbaux, MD, MSc Centre Hospitalier Regional Universitaire de Lille, France 5Live #ASCO20
5:36
Key Insights on Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA.
Diffuse Large B Cell Lymphoma
Charles Herbaux, MD, MSc Centre Hospitalier Regional Universitaire de Lille, France 5Live #ASCO20
Key Insights on Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA.
Diffuse Large B Cell Lymphoma Similar Videos
Similar Videos
-
Module 4_Integrating Novel Approaches in Clinical Practice & Key Takeaways_Gilles Salles, MD, PhD_Christopher Flowers, MD, MS_Laurie Sehn, MD, MPH
19:16
-
Beyond the Congress Video Edits Susan O'Brien_recap_#BeyondASH21recap
3:44
-
Module 2_Limitations of Traditional Therapies_Gilles Salles, MD, PhD_Christopher Flowers, MD, MS_Laurie Sehn, MD, MPH
10:50
